Kineta Inc - Company Profile
Powered by 
All the data and insights you need on Kineta Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Kineta Inc Strategy Report
- Understand Kineta Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Kineta Inc (Kineta), formerly Yumanity Therapeutics Inc, is a clinical stage development company focused on the development of next-generation immunotherapies. Kineta has successfully established its Innate Immunity Development Platform with the purpose of creating fully human antibodies that target the key mechanisms responsible for cancer immune resistance. These mechanisms include immuno-suppression, exhausted T cells, and poor tumor immunogenicity. Its major pipeline products include KVA12123, Anti-CD27 agonist mAb immunotherapy and Anti-CD24 antagonistmAb immunotherapy. Kineta is headquartered in Seattle, Washington, the US.
Headquarters
United States of America
Address
7683 Se 27th Street, Suite 481, Mercer Island, Washington, 98040
Website
kinetabio.com
Telephone
1 206 3780400
No of Employees
11
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KA (NASD)
Revenue (2022)
$5.4M
178.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
77.8%
(2022 vs 2021)
Market Cap*
$4.0M
Net Profit Margin (2022)
XYZ
92.0%
(2022 vs 2021)
* As of and is in US$
Kineta Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| KVA12123: VISTA blocking immunotherapy |
| Anti-CD27 agonistmAb immunotherap |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In September, the company entered into an agreement with Fred Hutchinson Cancer Center to evaluate VISTA expression as a potential biomarker in cancer patients from Kineta’s ongoing Phase 1/2 clinical trial evaluating KVA121. |
| 2022 | Acquisitions/Mergers/Takeovers | In December, the company merged with Yumanity Therapeutics. |
| 2022 | Contracts/Agreements | In October, the company entered into a partnership with Merck to evaluate KVA12123 in combination with KEYTRUDA (pembrolizumab) to treat patients with advanced solid tumors. |
Competitor Comparison
| Key Parameters | Kineta Inc | AbbVie Inc | Novartis AG | Gilead Sciences Inc | Vertex Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | United States of America |
| City | Mercer Island | North Chicago | Basel | Foster City | Boston |
| State/Province | Washington | Illinois | - | California | Massachusetts |
| No. of Employees | 11 | 50,000 | 76,057 | 18,000 | 5,400 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Shawn Iadonato | Chairman; Chief Executive Officer | Executive Board | - | 53 |
| Keith Baker | Chief Financial Officer | Senior Management | - | 56 |
| Thierry Guillaudeux, Ph.D. | Chief Scientific Officer | Senior Management | - | 56 |
| Craig W Philips | President | Senior Management | - | 63 |
| Pauline Kenny | Secretary; General Counsel | Senior Management | - | 50 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward